Amplia Therapeutics Limited (ASX:ATX)
0.1200
-0.0025 (-2.04%)
Feb 19, 2026, 3:45 PM AEST
Amplia Therapeutics Revenue
Amplia Therapeutics had revenue of 2.63M AUD in the half year ending September 30, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to 5.01M, up 46.79% year-over-year. In the fiscal year ending March 31, 2025, Amplia Therapeutics had annual revenue of 3.78M, down -15.03%.
Revenue (ttm)
5.01M
Revenue Growth
+46.79%
P/S Ratio
12.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
62.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.78M | -669.04K | -15.03% |
| Mar 31, 2024 | 4.45M | 3.26M | 274.34% |
| Mar 31, 2023 | 1.19M | -793.83K | -40.03% |
| Mar 31, 2022 | 1.98M | 449.80K | 29.33% |
| Mar 31, 2021 | 1.53M | 1.50M | 4,380.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 66.87M |
| Radiopharm Theranostics | 12.51M |
| Alterity Therapeutics | 5.44M |
| Imugene | 4.40M |
| Prescient Therapeutics | 4.36M |
| Proteomics International Laboratories | 3.31M |
| Cynata Therapeutics | 1.89M |
| Entropy Neurodynamics | 1.58M |
Amplia Therapeutics News
- 19 days ago - Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025 - GlobeNewsWire
- 5 weeks ago - ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM - GlobeNewsWire
- 2 months ago - Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium - GlobeNewsWire
- 2 months ago - Additional Confirmed Response Reported as Part of Amplia Investor Presentation - GlobeNewsWire
- 2 months ago - Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th - GlobeNewsWire
- 7 months ago - Bell Potter kicks off equity raisings for Amplia, Elsight - The Australian Financial Review